Drug intelligence / Profile preview

DA-5212-R

Development stage: Unknown
Lead developer: Dong-A ST

Overview

DA-5212-R is an investigational pharmaceutical drug developed by Dong-A ST for the treatment of functional dyspepsia. It has been evaluated in a phase 3 clinical trial as a control arm compared to DA-5212, with both drugs administered once daily for four weeks in adult patients diagnosed with functional dyspepsia. The precise mechanism of action for DA-5212-R remains unknown based on available public sources. The drug is not approved in any country and has no known adverse events reported from trials to date[1][5][6].

Beyond the preview

Go deeper on DA-5212-R.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DA-5212-R.

Explore the full profile